Established in late 1999

• Scientific/clinical resources

• Ethics committees

• Regulatory bodyTT - 2002

SAAVI aims to develop an

affordable, effective and

locally relevant preventative

HIV vaccine for southern

Africa

HIV genetic diversityHIV genetic diversityHIV genetic diversityHIV genetic diversity

CCCC

CC

CCCC

AAAA

AA AAAGAG

AGAG AGAGAEAE

AEAE AEAEGG

GG GG JJJJ

HH

BBBB BB BB

BBBBBBDD

DDDD

DDDD

FFFFKK

KK

CCCC

CCCCCC

CCCC

CC

CCCC

CC

CC

C. Williamson et al

Making the vaccine

Testing the vaccine

Ethicalissues

Advocacy& community

Others

TT - 2002

Immunologyassessment

Human Animal

What do we expect from What do we expect from an HIV vaccine?an HIV vaccine?

What do we expect from What do we expect from an HIV vaccine?an HIV vaccine?

““Viral load” in HIVViral load” in HIV““Viral load” in HIVViral load” in HIV

Am

ou

nt o

f HIV

5%

90%

Progress toAIDS in 5 years

Potential end-points of HIV-Potential end-points of HIV-vaccine efficacy trialsvaccine efficacy trials

Potential end-points of HIV-Potential end-points of HIV-vaccine efficacy trialsvaccine efficacy trials

TT - 2002

SAAVI ChallengesSAAVI ChallengesSAAVI ChallengesSAAVI Challenges

Making the vaccine

Testing the vaccine

Ethicalissues

Advocacy& community

Others

TT - 2002

Immunologyassessment

Human Animal

TT - 2002

Supporters and Funds

Source TOTAL 2001 TOTAL 2002Department of Health R 5,000,000 R 10,000,000Department of Arts, Culture, Science and TechnologyR 10,000,000 R 10,000,000Eskom R 7,500,000 R 15,000,000HIV Vaccine Trial Network R 7,000,000 R 8,000,000NIH Vaccine Development Research Committee (VDRG) R 0 R 18,000,000European Union R 5,000,000 R 5,000,000Corporation A R 10,000,000

TOTAL R 34,500,000 R 76,000,000

TT - 2002

1. Good vaccine candidates

2. HIV subtypes

3. Community involvement

4. Ethical studies

5. Access to product

6. Pricing

7. Technology transfer

Appropriate Clinical Trials

$30

mill

ion

TT - 2002

Manufacturing 1. Product?

2. When?

3. What dose?

4. Manufacturing plant

5. Personnel

6. Dose price

7. Distribution capacity

$350

mill

ion

•Clinical trials lot

•Bulk supply

TT - 2002

1. Government

2. Medicines Control Council

3. Ethics committees

4. Medical aids

5. Life Insurance

6. Blood transfusion services

7. State Vaccine Institute

Strategic nationalalliances

TT - 2002

Strategic international alliances

1. NIH

2. HVTN

3. IAVI

4. AAVP

5. EU

6. Public / private

CONCLUSIONSCONCLUSIONSCONCLUSIONSCONCLUSIONS

• SAAVI has dynamic team

• Different to all other initiatives

• Committed to excellence

• Massive / maturing challenges

• Consolidate and expand

TT - 2002